Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali
CRL shall invest another Rs. 200 crore for creation of additional beds
CRL shall invest another Rs. 200 crore for creation of additional beds
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
EBITDA before special items decreases to €4.08 billion (7.4%)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Subscribe To Our Newsletter & Stay Updated